Insights

Innovative Therapeutic Pipeline Imbrium Therapeutics has a diversified pipeline of investigational drugs targeting oncology, central nervous system disorders, and non-opioid pain management, indicating potential opportunities in partnering for early-stage drug development or licensing.

Strategic Collaborations The company's active collaboration with industry and academic partners, including recent development agreements with PureTech Health, opens avenues for joint ventures and licensing deals around their novel biologic therapeutics.

Focus on Non-Opioid Solutions Imbrium's focus on non-opioid treatments for pain and bladder syndromes aligns with current market trends, presenting opportunities to introduce complementary products or support for their non-addictive pain management portfolio.

Market Expansion Potential With recent FDA Orphan Drug designation and ongoing development in specialized areas, there is a strong potential for sales expansion into niche markets for rare diseases and underserved patient populations.

Financial Growth Indicators Having generated between $10 million and $25 million in revenue, Imbrium is poised for growth, offering opportunities for strategic investments, partnerships, and collaborations to accelerate their commercial pipeline.

Imbrium Therapeutics Tech Stack

Imbrium Therapeutics uses 8 technology products and services including Open Graph, Osano, MySQL, and more. Explore Imbrium Therapeutics's tech stack below.

  • Open Graph
    Content Management System
  • Osano
    Cookie Compliance
  • MySQL
    Database
  • oEmbed
    Dev Tools
  • Shopify
    E-commerce
  • jQuery
    Javascript Libraries
  • Yoast SEO
    Search Engines
  • Onsen UI
    Software Development

Media & News

Imbrium Therapeutics's Email Address Formats

Imbrium Therapeutics uses at least 1 format(s):
Imbrium Therapeutics Email FormatsExamplePercentage
First.Last@imbriumthera.comJohn.Doe@imbriumthera.com
49%
First.Middle@imbriumthera.comJohn.Michael@imbriumthera.com
1%
First.Last@imbriumthera.comJohn.Doe@imbriumthera.com
49%
First.Middle@imbriumthera.comJohn.Michael@imbriumthera.com
1%

Frequently Asked Questions

What is Imbrium Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Imbrium Therapeutics's official website is imbriumthera.com and has social profiles on LinkedIn.

What is Imbrium Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Imbrium Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Imbrium Therapeutics have currently?

Minus sign iconPlus sign icon
As of December 2025, Imbrium Therapeutics has approximately 30 employees across 1 continents, including North America. Key team members include Chief Science Officer: J. R.Head Of Licensing & Business Development: D. S.Head Of Biometrics: E. H.. Explore Imbrium Therapeutics's employee directory with LeadIQ.

What industry does Imbrium Therapeutics belong to?

Minus sign iconPlus sign icon
Imbrium Therapeutics operates in the Biotechnology Research industry.

What technology does Imbrium Therapeutics use?

Minus sign iconPlus sign icon
Imbrium Therapeutics's tech stack includes Open GraphOsanoMySQLoEmbedShopifyjQueryYoast SEOOnsen UI.

What is Imbrium Therapeutics's email format?

Minus sign iconPlus sign icon
Imbrium Therapeutics's email format typically follows the pattern of First.Last@imbriumthera.com. Find more Imbrium Therapeutics email formats with LeadIQ.

When was Imbrium Therapeutics founded?

Minus sign iconPlus sign icon
Imbrium Therapeutics was founded in 2018.

Imbrium Therapeutics

Biotechnology ResearchConnecticut, United States11-50 Employees

Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. We are pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. As an operating subsidiary of Purdue Pharma L.P., Imbrium strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians and health systems worldwide. We have built a robust and diversified pipeline of investigational drug candidates, and we actively collaborate with industry and academic partners to identify and advance future impactful medicines. 

LinkedIn posts may include discussion of investigational products that have not been approved by FDA, and for which safety or effectiveness have not been established. There is no guarantee they will successfully complete development or gain FDA approval.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $10M$25M

    Imbrium Therapeutics's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $10M$25M

    Imbrium Therapeutics's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.